Pharma and Biotech
| SVN-015 accepted into US NIDA funded programme | 03-Dec-2025 | 07:00 | RNS |
| Total Voting Rights | 31-Oct-2025 | 15:59 | RNS |
| Corporate Structure Update and Issue of Options | 31-Oct-2025 | 07:00 | RNS |
| Appoints global biopharma leader Paul Carter | 27-Oct-2025 | 07:00 | RNS |
| Raises £1.25 Million to Accelerate Programmes | 16-Oct-2025 | 07:00 | RNS |
| Half-year Report | 30-Sep-2025 | 07:00 | RNS |
| Solvonis secures exclusive CNS collaboration | 28-Aug-2025 | 07:00 | RNS |
| SVN-SDN-14 PTSD - Positive pre-clinical results | 12-Aug-2025 | 07:00 | RNS |
| Total Voting Rights | 31-Jul-2025 | 16:30 | RNS |
| Translational Bridging Studies | 22-Jul-2025 | 07:00 | RNS |
| Exercise of warrants | 18-Jul-2025 | 11:03 | RNS |
| £1m subscription to accelerate AI drug disc... | 11-Jul-2025 | 07:00 | RNS |
| Holding(s) in Company | 08-Jul-2025 | 07:00 | RNS |
| AGM Statement | 27-Jun-2025 | 14:38 | RNS |
| Holding(s) in Company | 27-Jun-2025 | 08:54 | RNS |
| Currency | UK Pounds |
| Share Price | 0.26p |
| Change Today | -0.010p |
| % Change | -3.77 % |
| 52 Week High | 0.39 |
| 52 Week Low | 0.12 |
| Volume | 12,002,718 |
| Shares Issued | 6,806m |
| Market Cap | £17.36m |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth | ![]() |
|---|
| No dividends found |
| Time | Volume / Share Price |
| 15:53 | 34,430 @ 0.26p |
| 15:00 | 674,230 @ 0.26p |
| 14:21 | 384,615 @ 0.26p |
| 14:19 | 55,001 @ 0.25p |
| 14:14 | 75,253 @ 0.25p |
| CEO | Anthony Tennyson |
| Chair | Dennis Purcell |
You are here: research